Arcellx and AstraZeneca take centre stage.

Five years after settling, GSK is again accused of breaching the Jemperli deal.

Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial. 

The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.

The company adds royalty aggregation to its R&D business.

And AbbVie and Genmab scoop their ASH presentation with new data.